STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show

STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The findings were presented by Wendel Naumann, MD, principal investigator of the trial, in a recent virtual presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting. Sutro Biopharma’s STRO-002 contains an antibody that specifically binds to folate receptor alpha (FRα), a protein found…

You must be logged in to read/download the full post.